Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Total Current Liabilities (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of Total Current Liabilities data on record, last reported at $21.0 million in Q3 2025.

  • For Q3 2025, Total Current Liabilities rose 38.54% year-over-year to $21.0 million; the TTM value through Sep 2025 reached $21.0 million, up 38.54%, while the annual FY2024 figure was $18.3 million, 3.06% down from the prior year.
  • Total Current Liabilities reached $21.0 million in Q3 2025 per TNXP's latest filing, up from $19.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $22.0 million in Q2 2024 and bottomed at $12.1 million in Q1 2025.
  • Average Total Current Liabilities over 3 years is $17.9 million, with a median of $18.4 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: soared 56.65% in 2024, then crashed 40.69% in 2025.
  • A 3-year view of Total Current Liabilities shows it stood at $18.9 million in 2023, then fell by 3.06% to $18.3 million in 2024, then grew by 14.88% to $21.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Current Liabilities were $21.0 million in Q3 2025, $19.1 million in Q2 2025, and $12.1 million in Q1 2025.